Retrospective analysis of impact of Köhne prognostic category and BRAF mutation status on survival in patients with RAS wild-type metastatic colore...

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter M. Peeters
Citation Annals of Oncology (2016) 27 (2): 102-117. 10.1093/annonc/mdw200
Authors M. Peeters1, S. Siena2, J.-. Douillard3, F. Rivera4, J. Taieb5, R. Koukakis6, G. Demonty7, C.-. Köhne8
  • 1Antwerp University Hospital, Edegem, Belgium, /
  • 2Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, and Università degli Studi di Milano, Milan, Italy, /
  • 3Institut de Cancérologie de l'Ouest (ICO) René Gauducheau, St Herblain, France, /
  • 4Hospital Universitario Marqués de Valdecilla, Santander, Spain, /
  • 5Paris Descartes University, Sorbonne Paris-Cité Hopital Européen Georges Pompidou, Paris, France, /
  • 6Amgen Ltd, Uxbridge, United Kingdom, /
  • 7Amgen (Europe) GmbH, Zug, Switzerland, /
  • 8Klinikum Oldenburg, Oldenburg, Germany, /


In the 20050181 study, second-line panitumumab + FOLFIRI significantly improved progression-free survival (PFS) vs. FOLFIRI alone in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC). It has previously been shown (Köhne et al. Ann Oncol 2002;13:308–17) that mCRC can be classified as high, medium and low prognostic risk based on four clinical parameters: Eastern Cooperative Oncology Group (ECOG) performance status, white blood cell count, alkaline phosphatase, and number of metastatic sites. BRAF mutation status has subsequently been identified as an additional negative prognostic marker in mCRC. We retrospectively analysed survival outcomes in patients from the 20050181 study classified by Köhne and BRAF prognostic risk.